The drop in Avid Bioservices shares is likely due to investor concerns over the preliminary Q3 financial results and the dilutive impact of the $160 million convertible notes placement. Convertible notes can lead to dilution of existing shares, which often negatively affects the stock price in the short term. Additionally, the preliminary financial results may have not met investor expectations, further contributing to the negative sentiment.